Biotech-focused venture capital firm Atlas Venture has successfully closed its fourteenth fund, which aims to invest in promising biotech startups. This fund has already generated exits totaling approximately $1.1 billion, with each exit yielding significant returns for investors. Atlas Venture continues to focus on innovative companies within the biotechnology sector, leveraging its expertise to identify and support high-potential ventures. The successful closure of this fund marks a significant milestone for the firm as it seeks to expand its portfolio and drive further growth in the biotech industry.